Open in Screener

LXRX

Lexicon Pharmaceuticals Inc

Feb 26 • 04:00PM ET

1.50

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Feb 19, 8:30 PMChairman's $353K insider stock purchase ignited 15.15% surge.

Peers: VRTX BIIB REGN BMRN INCY ALNY IONS NBIX KNSA ALLO

| Held by: VTI VXF SCHA PRFZ VHT SCHB QQQS BTEC

Index	-	P/E	-	EPS (ttm)	-0.19	Insider Own	57.53%	Shs Outstand	363.40M	Perf Week	-1.32%
Market Cap	593.20M	Forward P/E	-	EPS next Y	-0.24	Insider Trans	0.91%	Shs Float	167.81M	Perf Month	-12.28%
Enterprise Value	542.19M	PEG	-	EPS next Q	-0.07	Inst Own	23.06%	Short Float	14.65%	Perf Quarter	5.63%
Income	-68.58M	P/S	8.37	EPS this Y	73.50%	Inst Trans	-28.76%	Short Ratio	10.02	Perf Half Y	31.58%
Sales	70.86M	P/B	4.54	EPS next Y	-46.49%	ROA	-26.02%	Short Interest	24.58M	Perf YTD	30.43%
Book/sh	0.33	P/C	5.12	EPS next 5Y	28.96%	ROE	-45.92%	52W High	1.83 -18.03%	Perf Year	112.28%
Cash/sh	0.29	P/FCF	-	EPS past 3/5Y	-1.29% -	ROIC	-37.38%	52W Low	0.28 428.91%	Perf 3Y	-32.74%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	370.72% -37.35%	Gross Margin	98.52%	Volatility	6.94% 8.96%	Perf 5Y	-79.14%
Dividend TTM	-	EV/Sales	7.65	EPS Y/Y TTM	74.58%	Oper. Margin	-81.80%	ATR (14)	0.12	Perf 10Y	-83.46%
Dividend Ex-Date	-	Quick Ratio	5.63	Sales Y/Y TTM	1255.21%	Profit Margin	-96.77%	RSI (14)	57.73	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	5.64	EPS Q/Q	80.42%	SMA20	11.40%	Beta	0.97	Target Price	2.92
Payout	-	Debt/Eq	0.54	Sales Q/Q	710.40%	SMA50	14.43%	Rel Volume	0.73	Prev Close	1.50
Employees	103	LT Debt/Eq	0.53	Earnings	Mar 05 BMO	SMA200	27.48%	Avg Volume	2.45M	Price	1.50
IPO	Apr 07, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	39.39% 205.04%	Trades		Volume	1,801,035	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-05-25	Downgrade	Leerink Partners	Outperform → Market Perform	$2 → $1
Jun-17-24	Initiated	H.C. Wainwright	Buy	$10
Apr-30-24	Initiated	Leerink Partners	Outperform	$5
Mar-07-23	Initiated	Jefferies	Hold	$3
Aug-12-22	Initiated	Piper Sandler	Overweight	$10
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral	$7
Jan-29-21	Downgrade	Wedbush	Outperform → Neutral	$2 → $8
Dec-08-20	Upgrade	Citigroup	Neutral → Buy
Nov-18-20	Upgrade	Gabelli & Co	Hold → Buy
Dec-11-19	Downgrade	Gabelli & Co	Buy → Hold
Nov-08-19	Downgrade	Citigroup	Buy → Neutral	$3 → $4
Sep-11-19	Upgrade	Gabelli & Co	Hold → Buy	$3
Jul-29-19	Downgrade	Stifel	Buy → Hold	$10 → $4
Mar-25-19	Upgrade	Gabelli & Co	Sell → Hold
Jul-31-18	Reiterated	Stifel	Buy	$24 → $23
Feb-23-18	Downgrade	Needham	Buy → Hold
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight	$10
Mar-01-17	Reiterated	Wedbush	Outperform	$33 → $38
Mar-01-17	Reiterated	H.C. Wainwright	Buy	$26 → $27
Oct-07-16	Initiated	H.C. Wainwright	Buy	$26

Show Previous Ratings

Today 08:30AM	Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026 (GlobeNewswire)
Feb-06-26 05:17PM	Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement (GlobeNewswire)
Jan-30-26 02:58PM	Citi Raises Lexicon Pharmaceuticals (LXRX) Outlook on Strength of Novo Nordisk Partnership Milestones (Insider Monkey) -19.44%
02:50AM	Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement (GlobeNewswire)
Jan-29-26 04:31PM	Lexicon Announces Proposed Public Offering of Common Stock (GlobeNewswire)
07:05AM	Loading…
07:05AM	Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? (Zacks)
Jan-23-26 08:30AM	Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary (GlobeNewswire)
Jan-21-26 08:30AM	Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain (GlobeNewswire) +19.08%
Jan-12-26 07:30AM	Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-09-26 08:30AM	Lexicon Pharmaceuticals Publishes "Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain" (GlobeNewswire)
Jan-07-26 08:30AM	Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-25 08:30AM	Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 (GlobeNewswire)
Dec-05-25 08:30AM	Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum (GlobeNewswire)
Nov-25-25 08:30AM	Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences (GlobeNewswire)
Nov-24-25 09:47AM	Lexicon Pharmaceuticals, Inc. (LXRX) Makes Progress in Product Pipeline Development (Insider Monkey) +5.97%
08:30AM	Loading…
Nov-11-25 08:30AM	Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference (GlobeNewswire) +9.86%
Nov-08-25 02:30PM	Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 (GlobeNewswire)
Nov-06-25 08:50AM	Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:47AM	Lexicon: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates (GlobeNewswire)
Nov-05-25 05:35PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-04-25 08:30AM	Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans (GlobeNewswire)
Oct-30-25 08:30AM	Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-14-25 08:00AM	Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit (GlobeNewswire)
Oct-08-25 07:59AM	Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain (GlobeNewswire) -5.92%
Sep-22-25 04:00PM	Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes (GlobeNewswire)
Sep-17-25 07:00AM	Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings (GlobeNewswire)
Sep-11-25 08:30AM	Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings (GlobeNewswire)
Sep-08-25 08:30AM	Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes (GlobeNewswire)
Sep-04-25 08:30AM	Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025 (GlobeNewswire)
08:30AM	Loading…
Sep-03-25 08:30AM	Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 (GlobeNewswire)
Sep-02-25 08:30AM	Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress (GlobeNewswire)
Aug-27-25 08:30AM	Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Aug-08-25 12:00PM	Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-06-25 08:45AM	Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates (Zacks) +9.52%
07:47AM	Lexicon: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-05-25 06:35PM	Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates (Zacks) -6.25%
Jul-31-25 08:00AM	Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Jul-23-25 08:00AM	Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
Jul-20-25 12:35AM	H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) (Insider Monkey)
Jul-18-25 08:00AM	Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) (GlobeNewswire) -8.89%
Jun-23-25 08:00AM	Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) (GlobeNewswire)
Jun-18-25 08:30AM	Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) (GlobeNewswire)
Jun-10-25 09:08AM	Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM (Zacks) -5.91%
Jun-06-25 11:52AM	KURA Stock Rises More Than 15% This Past Week: Here's Why (Zacks) +6.93%
11:35AM	TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy (Zacks)
Jun-05-25 01:03PM	Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio? (Zacks) +8.46%
12:55PM	Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success (Zacks)
Jun-04-25 12:17PM	JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer (Zacks)
10:46AM	SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease (Zacks)
Jun-03-25 11:14AM	Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug (Zacks)
09:43AM	Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III (Zacks)
Jun-02-25 10:53AM	MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study (Zacks)
May-30-25 10:20AM	NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study (Zacks) -5.03%
08:59AM	IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus (Zacks)
May-29-25 11:44AM	BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications (Zacks) -5.66%
10:50AM	CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer (Zacks)
08:00AM	Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-25 11:09AM	RCKT Stock Tanks on Patient Death in Danon Disease Study (Zacks)
11:07AM	TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate (Zacks)
10:43AM	VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval (Zacks)
May-27-25 10:46AM	AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer (Zacks)
May-26-25 11:44AM	GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma (Zacks)
11:25AM	SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease (Zacks)
May-21-25 11:19AM	Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential (Insider Monkey) +7.65%
May-19-25 08:00AM	SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology (GlobeNewswire)
May-15-25 10:00AM	ETFs to Capitalize on the Novo Nordisk-Septerna Deal (Zacks)
May-14-25 09:32AM	Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna (Yahoo Finance) -15.57%
09:32AM	Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna (Yahoo Finance)
03:18AM	Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... (GuruFocus.com)
May-13-25 05:10PM	Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -6.51%
04:06PM	Lexicon: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
May-12-25 08:50AM	Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-25 07:00PM	Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 04:30PM	Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference (GlobeNewswire) -8.90%
08:00AM	Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 (GlobeNewswire)
Apr-29-25 02:29PM	Growth Is Priced Out Of Novo Nordisk (Seeking Alpha)
Apr-02-25 10:18AM	LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? (Zacks) +8.40%
08:00AM	Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-28-25 06:10PM	Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) (Seeking Alpha) +64.13% -19.23%
04:17PM	Novo Nordisk Inks Its Second Big Obesity Deal In A Week And It's Not For A GLP-1 (Investor's Business Daily)
01:04PM	Novo Nordisk strikes $1bn deal for Lexicons oral obesity drug (Pharmaceutical Technology)
07:30AM	Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851 (GlobeNewswire)
Mar-07-25 08:30AM	Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 (GlobeNewswire) +6.55%
02:17AM	Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Mar-06-25 05:10PM	Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +9.43%
04:18PM	Lexicon: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-04-25 04:15PM	Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 (GlobeNewswire) +11.00%
Mar-03-25 07:00AM	Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain (GlobeNewswire) -58.17%
Mar-02-25 04:13PM	Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain (GlobeNewswire)
Feb-18-25 08:00AM	Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE) (GlobeNewswire)
Jan-21-25 08:00AM	Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain (GlobeNewswire) +14.25%
Jan-06-25 09:16AM	Heres Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10 (Insider Monkey) +15.94%
Jan-02-25 08:00AM	Lexicon Appoints Scott Coiante as Chief Financial Officer (GlobeNewswire) +5.23%
Dec-20-24 04:30PM	Lexicon Announces Receipt of Complete Response Letter for Zynquista (sotagliflozin) (GlobeNewswire) +15.71%
Nov-27-24 07:30AM	Lexicon completes subject enrolment for DPNP trial of LX9211 (Clinical Trials Arena)
Nov-26-24 08:00AM	Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) (GlobeNewswire)

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DEBBANE RAYMOND	Director	Feb 23 '26	Buy	1.47	100,000	147,000	1,904,186	Feb 25 07:00 AM
DEBBANE RAYMOND	Director	Feb 20 '26	Buy	1.48	100,000	147,790	1,804,186	Feb 23 07:49 AM
DEBBANE RAYMOND	Director	Feb 19 '26	Buy	1.44	50,000	71,965	1,704,186	Feb 23 07:49 AM
DEBBANE RAYMOND	Director	Feb 18 '26	Buy	1.32	133,688	176,468	1,654,186	Feb 18 04:30 PM
DEBBANE RAYMOND	Director	Feb 17 '26	Buy	1.31	76,857	100,544	1,520,498	Feb 18 04:30 PM
DEBBANE RAYMOND	Director	Feb 13 '26	Buy	1.31	57,952	75,877	1,443,641	Feb 18 04:30 PM
Invus Global Management, LLC	Director	Feb 02 '26	Buy	1.30	1,538,462	2,000,001	1,538,462	Feb 04 04:25 PM
Swain Judith L	Director	May 13 '25	Option Exercise	0.00	36,810	0	85,174	May 13 05:52 PM
Sullivan Diane E.	Director	May 13 '25	Option Exercise	0.00	36,810	0	36,810	May 13 05:51 PM
SOBECKI CHRISTOPHER J	Director	May 13 '25	Option Exercise	0.00	36,810	0	203,865	May 13 05:50 PM
BARKER SAM L	Director	May 13 '25	Option Exercise	0.00	36,810	0	124,459	May 13 05:50 PM
Amouyal Philippe	Director	May 13 '25	Option Exercise	0.00	36,810	0	285,174	May 13 05:49 PM
DEBBANE RAYMOND	Director	May 13 '25	Option Exercise	0.00	36,810	0	1,385,689	May 13 05:48 PM

Open in Screener

PZZA

Papa John's International, Inc

Feb 26 • 04:00PM ET

30.91

-2.92 -8.63 %

Consumer Cyclical • Restaurants • USA • NASD

PZZA Papa John's International, Inc daily Stock Chart

Peers: MCD DPZ YUM QSR SBUX CMG WING DRI BJRI CAKE

| Held by: IJR VTI IWM VB VBR VXF SPSM IWN IJS VTWO

Index	RUT	P/E	27.26	EPS (ttm)	1.13	Insider Own	1.26%	Shs Outstand	32.79M	Perf Week	-5.13%
Market Cap	1.01B	Forward P/E	14.16	EPS next Y	2.18	Insider Trans	0.00%	Shs Float	32.38M	Perf Month	-14.80%
Enterprise Value	1.94B	PEG	-	EPS next Q	0.40	Inst Own	107.00%	Short Float	11.27%	Perf Quarter	-23.62%
Income	37.38M	P/S	0.49	EPS this Y	28.83%	Inst Trans	-7.50%	Short Ratio	3.95	Perf Half Y	-36.48%
Sales	2.09B	P/B	-	EPS next Y	18.47%	ROA	4.30%	Short Interest	3.65M	Perf YTD	-19.69%
Book/sh	-13.40	P/C	26.01	EPS next 5Y	-	ROE	-	52W High	55.74 -44.55%	Perf Year	-33.15%
Cash/sh	1.19	P/FCF	12.79	EPS past 3/5Y	180.28% -	ROIC	7.90%	52W Low	30.16 2.49%	Perf 3Y	-63.90%
Dividend Est.	1.89 (6.10%)	EV/EBITDA	10.12	Sales past 3/5Y	-0.15% 4.93%	Gross Margin	16.62%	Volatility	5.94% 4.48%	Perf 5Y	-65.73%
Dividend TTM	1.84 (5.95%)	EV/Sales	0.93	EPS Y/Y TTM	-60.71%	Oper. Margin	5.41%	ATR (14)	1.60	Perf 10Y	-49.39%
Dividend Ex-Date	Feb 09, 2026	Quick Ratio	0.76	Sales Y/Y TTM	-0.64%	Profit Margin	1.79%	RSI (14)	35.65	Recom	2.50
Dividend Gr. 3/5Y	16.96% 15.38%	Current Ratio	0.87	EPS Q/Q	-89.40%	SMA20	-7.73%	Beta	1.21	Target Price	43.29
Payout	72.48%	Debt/Eq	-	Sales Q/Q	0.27%	SMA50	-15.45%	Rel Volume	3.38	Prev Close	33.83
Employees	11400	LT Debt/Eq	-	Earnings	Feb 26 BMO	SMA200	-28.98%	Avg Volume	924.50K	Price	30.91
IPO	Jun 08, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.45% -3.70%	Trades		Volume	3,123,339	Change	-8.63%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-28-25	Initiated	Mizuho	Neutral	$58
Oct-06-25	Downgrade	BofA Securities	Buy → Neutral	$50
Nov-14-24	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Apr-22-24	Upgrade	Stifel	Sell → Hold	$65 → $60
Apr-12-24	Resumed	Stephens	Overweight	$75
Mar-22-24	Downgrade	BTIG Research	Buy → Neutral
Jan-05-24	Downgrade	Oppenheimer	Outperform → Perform
Jan-04-24	Downgrade	Stifel	Hold → Sell	$65
Nov-03-23	Downgrade	Stifel	Buy → Hold	$81 → $65
Oct-26-23	Downgrade	Wedbush	Outperform → Neutral	$95
Oct-19-23	Initiated	Deutsche Bank	Hold	$71
Sep-01-23	Upgrade	Wedbush	Neutral → Outperform	$80 → $95
Jun-14-23	Initiated	Piper Sandler	Neutral	$77
Jan-25-23	Initiated	BofA Securities	Buy	$103
Dec-21-22	Downgrade	Wedbush	Outperform → Neutral
Nov-07-22	Downgrade	Northcoast	Buy → Neutral
Sep-23-22	Initiated	Stephens	Overweight	$100
Feb-02-22	Upgrade	Northcoast	Neutral → Buy	$147
Nov-12-21	Initiated	The Benchmark Company	Buy	$145
Nov-05-21	Downgrade	Northcoast	Buy → Neutral	$136

Show Previous Ratings

Today 04:16PM	Papa John's International Inc (PZZA) Q4 2025 Earnings Call Highlights: Navigating Challenges ... (GuruFocus.com) -8.63%
03:34PM	Papa John's to close 300 restaurants as it moves to cut costs (CBS News)
02:20PM	Pizza Hut rival closing 300 locations nationwide (TheStreet)
12:30PM	Papa John's (PZZA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
12:28PM	Tight Wallets, Heavy Promotions Pressure Papa John's Results (Benzinga)
12:15PM	Loading…
12:15PM	Papa John's (PZZA) Q4 Earnings Top Estimates (Zacks)
10:10AM	Papa Johns International Closing Hundreds of Pizza Shops (The Wall Street Journal)
08:22AM	Papa John's Posts Lower Profit, Revenue (The Wall Street Journal)
07:37AM	Papa John's: Q4 Earnings Snapshot (Associated Press Finance)
07:08AM	Papa John's (NASDAQ:PZZA) Misses Q4 CY2025 Revenue Estimates (StockStory)
07:00AM	Papa Johns Announces Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-25-26 11:16AM	Mizuho Cuts Papa John's (PZZA) Target as Part of Restaurant Industry Outlook (Insider Monkey)
Feb-24-26 10:10PM	Papa John's (PZZA) Q4 Earnings: What To Expect (StockStory) +5.43%
12:20PM	What's in Store for These 3 Restaurant Stocks in Q4 Earnings? (Zacks)
08:50AM	First Watch Restaurant Group, Inc. (FWRG) Tops Q4 Earnings and Revenue Estimates (Zacks)
10:14PM	Loading…
Feb-23-26 10:14PM	Pete Hegseth Once Laughed Off the Pentagon Pizza Theory - Now the Delivery Surge Is Back (Benzinga)
10:05AM	Dominos Pizza Stock Rises After Earnings. The Chain Takes More Market Share. (Barrons.com)
09:20AM	Papa John's to Report Q4 Earnings: What's in the Offing for the Stock? (Zacks)
06:05AM	Domino's Pizza Posts Another Quarter of Growth as It Takes More Market Share (Barrons.com)
Feb-19-26 10:00AM	Papa John's (PZZA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-16-26 11:36PM	3 of Wall Street's Favorite Stocks We Approach with Caution (StockStory)
Feb-11-26 09:00AM	Papa Johns Makes a Bold Run to Become the First Pizzeria Awarded a MICHELIN Star (Business Wire)
Feb-06-26 07:30AM	Papa Johns Canada Launches Pizza My Heart for Valentine's Day (GlobeNewswire)
Feb-05-26 11:00PM	Papa John's (PZZA): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Feb-01-26 11:32PM	3 Profitable Stocks Walking a Fine Line (StockStory)
Jan-28-26 11:33PM	1 Small-Cap Stock Worth Your Attention and 2 We Turn Down (StockStory)
01:23PM	Domino's Pizza Faces Tough Comps Ahead Of Q4: Analyst (Benzinga)
12:00PM	The Wait is Over: Pan Pizza Has Entered a New Era at Papa Johns (Business Wire)
Jan-26-26 07:00AM	Papa Johns Declares Quarterly Dividend (Business Wire)
Jan-22-26 07:00AM	Papa Johns to Report Fourth Quarter and Full Year 2025 Results on February 26, 2026 (Business Wire)
12:47PM	Loading…
Jan-19-26 12:47PM	Papa John's leans into growing trend Chipotle embraced (TheStreet)
Jan-18-26 10:35PM	Unpacking Q3 Earnings: Papa John's (NASDAQ:PZZA) In The Context Of Other Traditional Fast Food Stocks (StockStory)
Jan-16-26 04:10PM	Why Papa John's (PZZA) Stock Is Down Today (StockStory) +5.23%
Jan-15-26 09:11AM	Papa Johns Is Testing Protein-Infused Dough With the Protein Crust Pizza (Business Wire)
Jan-14-26 09:26AM	Delivery & Carryout Both Rising, Is DPZ Entering a New Balance Phase? (Zacks)
09:25AM	Company News for Jan 14, 2026 (Zacks)
07:36AM	Papa John's Rewires U.S. Restaurants (GuruFocus.com)
Jan-12-26 04:01PM	Papa Johns Partners with PAR Technology to Power POS and OPS Transformation Across 3,200 U.S. Restaurants (Business Wire)
11:59AM	Papa John's Launches AI-Powered Omnichannel Ordering With Google Cloud (Zacks)
Jan-11-26 10:00AM	Google Bets on AI-Based Shopping With New AI Agents for Retailers (The Wall Street Journal)
09:57AM	Papa Johns and Google Cloud Reimagine the Future of Food Ordering to Better Serve Customers (PR Newswire)
Jan-09-26 11:30AM	Why Papa John's (PZZA) Stock Is Down Today (StockStory)
Jan-08-26 12:17PM	Cautious Analyst Sentiment on Papa John's (PZZA) As Refranchising and Cost Reductions Drive Strategy (Insider Monkey)
Jan-06-26 07:00AM	Papa Johns and the CHL Launch "Champions of Tomorrow" to Support Canada's Young Hockey Players (GlobeNewswire)
Jan-02-26 01:45PM	Why Papa John's (PZZA) Stock Is Trading Up Today (StockStory)
Dec-23-25 12:15AM	Analysts Stick to Hold Ratings on Papa John's (PZZA) (Insider Monkey)
Dec-22-25 07:30AM	Shaquille O'Neal Won't Share His Fortune With His Kids: 'I'm Not Going To Hand It to You' (Benzinga)
Dec-20-25 03:51PM	Shaquille O'Neal Won't Share His Fortune With His Kids: 'I'm Not Going To Hand It to You' (Benzinga)
Dec-14-25 11:32PM	3 Stocks Under $50 We Approach with Caution (StockStory)
Dec-04-25 11:38PM	1 Cash-Producing Stock with Promising Prospects and 2 We Find Risky (StockStory)
Dec-03-25 03:26PM	Papa John's (PZZA) Stock Is Up, What You Need To Know (StockStory)
Nov-26-25 05:46AM	Papa Johns hands 85 US stores to Pie Investments in refranchise deal (Verdict Food Service)
Nov-25-25 05:31PM	Papa Johns Completes Strategic Refranchising and New Restaurant Development Agreement with Franchisee Chris Patel of Pie Investments (Business Wire)
Nov-19-25 05:21AM	Papa Johns replaces North America president in management shake-up (Verdict Food Service)
Nov-18-25 04:30PM	Papa John's: Starboard CEO on potentially getting involved again (Yahoo Finance Video)
07:30AM	Papa Johns Promotes Ravi Thanawala to Chief Financial Officer and President, North America (Business Wire)
Nov-17-25 05:25PM	Investors Get Cold Feet in a Hot Stock Market (Motley Fool)
04:53AM	Irenic Capital picks stake in Papa Johns (Verdict Food Service)
Nov-13-25 01:28PM	Activist investors make Wall Street 'efficient': Starboard CEO (Yahoo Finance Video)
Nov-12-25 12:39PM	Papa John's $2.7 Billion Takeover Bid: A Price on Untapped Value (MarketBeat)
07:16AM	Papa John's Falls After Takeover Talk Fizzles Out (GuruFocus.com)
Nov-11-25 03:40PM	Why Papa John's (PZZA) Shares Are Trading Lower Today (StockStory)
10:30AM	Papa Johns stock falls after buyout report disappears from website (Investing.com)
10:25AM	Papa Johns Stock Surged on False Takeover Report. Shares Are Falling Today. (Barrons.com)
Nov-10-25 12:20PM	Papa John's Stock Surges on Reported Private Takeover-Again (Barrons.com) +7.04%
12:14PM	Palantir & tech lead gains, Papa John's reported deal to go private (Yahoo Finance Video)
Nov-09-25 07:30AM	Valuation worries, record-long government shutdown hang over markets: What to watch this week (Yahoo Finance)
07:30AM	Record-long government shutdown, valuation worries in focus for markets: What to watch this week (Yahoo Finance)
Nov-08-25 08:31AM	Gen Z is under financial pressure. Fast-casual chains are bearing the brunt. (Yahoo Finance)
Nov-06-25 04:19PM	Why breakups are in vogue for restaurant chains and Big Food (Yahoo Finance)
02:05PM	Papa John's International Inc (PZZA) Q3 2025 Earnings Call Highlights: Navigating Challenges ... (GuruFocus.com)
11:53AM	Papa John's sales suffer as customers downsize to medium pizzas with fewer toppings (MarketWatch)
10:30AM	Here's What Key Metrics Tell Us About Papa John's (PZZA) Q3 Earnings (Zacks)
09:44AM	Papa John's Touts Turnaround Plan but Stays 'Open-Minded' (The Wall Street Journal)
08:20AM	Papa John's (PZZA) Q3 Earnings and Revenues Miss Estimates (Zacks)
07:49AM	Papa John's (NASDAQ:PZZA) Misses Q3 Sales Expectations, Stock Drops (StockStory)
07:20AM	Papa John's: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Papa Johns Announces Third Quarter 2025 Financial Results (Business Wire)
Nov-05-25 08:43PM	Pizza Hut may be heading toward make-or-break moment (TheStreet) -5.08%
01:30PM	Papa John's earnings, reportedly withdrawn Apollo bid: What to know (Yahoo Finance Video)
11:32AM	Papa John's Crashes 21% After Apollo Walks--And Yum Wants Out of Pizza Hut Too (GuruFocus.com)
07:11AM	Apollo retracts takeover proposal for Papa Johns (Verdict Food Service)
Nov-04-25 10:10PM	Papa John's Earnings: What To Look For From PZZA (StockStory) -9.98%
03:56PM	Apple reportedly eyes a budget laptop, Denny's to go private (Yahoo Finance Video)
03:28PM	Papa Johns Drops After Report Says Deal Is Shelved (The Wall Street Journal)
03:28PM	?Papa John's Slides After Deal Reportedly Shelved (The Wall Street Journal)
03:08PM	Papa Johns Stock Tumbles on Report That Apollo Wont Take Pizza Chain Private (Barrons.com)
02:33PM	Papa Johns shares plunge after Apollo reportedly withdraws takeover bid (Investing.com)
02:16PM	Papa Johns Sinks Most Since 2020 on Report Apollo Pulled Bid (Bloomberg)
11:15AM	Yum! Brands Explores Sale of Pizza Hut. The Stock Rises. (Barrons.com)
08:10AM	Yum Brands (YUM) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Nov-03-25 01:00PM	Bigger, Bolder, Better: Papa Johns Redefines Pizza Night with The Grand Papa Pizza (Business Wire)
Nov-02-25 04:16PM	Corporate America's hefty profit streak continues amid worries over job market (MarketWatch)
Oct-30-25 10:00AM	Earnings Preview: Papa John's (PZZA) Q3 Earnings Expected to Decline (Zacks)
Oct-29-25 04:01PM	Papa Johns Declares Quarterly Dividend (Business Wire)
07:55AM	Brinker International (EAT) Q1 Earnings and Revenues Surpass Estimates (Zacks)
Oct-28-25 04:30AM	Bear of the Day: Papa John's International (PZZA) (Zacks)
03:55AM	ASML and Papa John's have been highlighted as Zacks Bull and Bear of the Day (Zacks)
Oct-27-25 03:17AM	1 Momentum Stock for Long-Term Investors and 2 We Ignore (StockStory) -6.73%
Oct-24-25 04:36AM	Why This Michigan-Based Company Could Be a Top Pick for Retail Investors (Motley Fool)

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

LXRX

Lexicon Pharmaceuticals Inc

PZZA

Papa John's International, Inc

Upgrade your FINVIZ experience